Document is current
Any future updates will be listed below
-
Authors
Sumida, Tomokazu S. http://orcid.org/0000-0002-9806-2642
Dulberg, Shai http://orcid.org/0000-0001-8304-5324
Schupp, Jonas C. http://orcid.org/0000-0002-7714-8076
Lincoln, Matthew R. http://orcid.org/0000-0003-2962-6253
Stillwell, Helen A.
Axisa, Pierre-Paul http://orcid.org/0000-0003-1446-3922
Comi, Michela http://orcid.org/0000-0002-0109-4868
Unterman, Avraham http://orcid.org/0000-0003-0965-3326
Kaminski, Naftali http://orcid.org/0000-0001-5917-4601
Madi, Asaf http://orcid.org/0000-0003-3441-3228
Kuchroo, Vijay K.
Hafler, David A. http://orcid.org/0000-0003-4664-535X
- License Information
-
More Information
Article History
Received: 21 December 2020
Accepted: 3 February 2022
First Online: 17 March 2022
Competing interests
: D.A.H. has received research funding from Bristol-Myers Squibb, Sanofi and Genentech. He has been a consultant for Bristol-Myers Squibb, Compass Therapeutics, EMD Serono, Genentech and Sanofi Genzyme over the last 3 years. Further information about funding is available at. V.K.K. has an ownership interest and is a member of the SAB for Tizona Therapeutics. V.K.K. is also a cofounder and has an ownership interest, and is a member of the SAB in Celsius Therapeutics and Bicara Therapeutics. V.K.K.’s interests were reviewed and managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict-of-interest policies. N.K. served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira and Astra Zeneca over the last 3 years, and reports Equity in Pliant and a grant from Veracyte and nonfinancial support from MiRagen and Astra Zeneca. He has intellectual property (IP) on new biomarkers and therapeutics in idiopathic pulmonary fibrosis (IPF) licensed to Biotech. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
